Breast Cancer Res.

Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study.

Gunnarsdottir FB, Bendahl PO, Johansson A, ..., Bergenfelz C, Larsson AM

Breast Cancer Res. 25 (1) 29 [2023-03-21; online 2023-03-21]

Bioinformatics Support and Infrastructure [Collaborative] Bioinformatics Support, Infrastructure and Training [Collaborative]

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.

Kaminska K, Akrap N, Staaf J, ..., Bosch A, Honeth G

Breast Cancer Res. 23 (1) 26 [2021-02-18; online 2021-02-18]

Clinical Genomics Lund [Service]

Clonal relatedness in tumour pairs of breast cancer patients.

Biermann J, Parris TZ, Nemes S, ..., Karlsson P, Helou K

Breast Cancer Res. 20 (1) 96 [2018-08-09; online 2018-08-09]

Bioinformatics Compute and Storage [Service] Bioinformatics Support and Infrastructure [Service] Bioinformatics Support, Infrastructure and Training [Service] NGI Stockholm (Genomics Applications) [Service] NGI Stockholm (Genomics Production) [Service] NGI Uppsala (SNP&SEQ Technology Platform) [Service] National Genomics Infrastructure [Service]

Affinity proteomic profiling of plasma for proteins associated to area-based mammographic breast density.

Byström S, Eklund M, Hong MG, ..., Schwenk JM, Gabrielson M

Breast Cancer Res. 20 (1) 14 [2018-02-14; online 2018-02-14]

Affinity Proteomics Stockholm [Collaborative] Bioinformatics Compute and Storage [Service]

Determining breast cancer histological grade from RNA-sequencing data.

Wang M, Klevebring D, Lindberg J, ..., Grönberg H, Rantalainen M

Breast Cancer Res. 18 (1) 48 [2016-05-10; online 2016-05-10]

Bioinformatics Compute and Storage [Service] NGI Stockholm (Genomics Applications) [Service] NGI Stockholm (Genomics Production) [Service] National Genomics Infrastructure [Service]

Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer.

O'Leary PC, Terrile M, Bajor M, ..., Zagozdzon R, Gallagher WM

Breast Cancer Res. 16 (4) R79 [2014-07-10; online 2014-07-10]

Tissue Profiling

Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.

Brennan DJ, Laursen H, O'Connor DP, ..., Rydén L, Jirström K

Breast Cancer Res. 13 (1) R12 [2011-01-31; online 2011-01-31]

Tissue Profiling